same population to test its efficacy in not just Pacific Islanders, but all youth.
Funding Acknowledgements: no funding

REFERENCES:
1. Birmaher, B.; et al. “Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders”.

184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

William Martin, PhD1; Christine Graham, PhD2; Linda Morrow, MD3; Carine Beysen, DPhil3; Frederico G.S. Toledo, MD4; Daiva Bajorunas, MD5; Ying Jiang, PhD7; Bernard Silverman, MD9; David McDonnell, MD9; Mark N. Namechuk, PhD10; and John W. Newcomer, MD11

1 Senior Director, Clinical Operations, Alkermes, Inc., Waltham, MA
2 Associate Medical Director, Clinical Research, Alkermes, Inc., Waltham, MA
3 Chief Medical Officer, ProSciento, Inc., Chula Vista CA
4 Senior Director, Clinical Research Innovation Services, ProSciento, Inc., Chula Vista CA
5 Associate Professor of Medicine, University of Pittsburgh, Pittsburgh, PA
6 Chief Scientific and Medical Officer, Vault Bioventures, San Diego, CA
7 Director, Biostatistics, Alkermes, Inc., Waltham, MA
8 Vice President, Clinical Strategy, Alkermes, Inc., Waltham, MA
9 Executive Medical Director, Clinical Science, Alkermes Pharma Ireland Limited, Dublin, Ireland
10 Senior Vice President, Research, Alkermes, Inc., Waltham, MA
11 President and Chief Executive Officer, Thriving Mind South Florida, Miami, FL

ABSTRACT: Background: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for schizophrenia to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The objective of this phase 1 exploratory study was to assess metabolic treatment effects of OLZ/SAM.

METHODS: Healthy, non-obese adults (18–40 years) were randomized 2:2:1 to once-daily OLZ/SAM, olanzapine, or placebo for 21 days. Assessments included oral glucose tolerance test (OGTT), hyperinsulinemic-euglycemic clamp, weight gain, and adverse event (AE) monitoring. Treatment effects were estimated with analysis of covariance.

RESULTS: Sixty subjects were randomized (OLZ/SAM, n=24; olanzapine, n=24; placebo, n=12); 19 (79.2%), 22 (91.7%), and 11 (91.7%), respectively, completed the study. In the OGTT, olanzapine led to significant hyperinsulinemia (P<0.0001) and significantly reduced insulin sensitivity (2-hour Matsuda index) at day 19 vs baseline (P=0.0012), changes not observed with OLZ/SAM. No significant between-group differences were observed for change from baseline in clamp-derived insulin sensitivity index at day 21. Least squares mean weight change from baseline was similar with OLZ/SAM (3.16 kg) and olanzapine (2.87 kg); both were significantly higher than placebo (0.57 kg; both P<0.01). Caloric intake significantly decreased from baseline to day 22 with OLZ/SAM (P=0.015) but not with olanzapine or placebo. Forty-nine subjects (81.7%) experienced ≥1 AE (OLZ/SAM, 87.5%; olanzapine, 79.2%; placebo, 75.0%).

CONCLUSIONS: In this exploratory study, hyperinsulinemia and decreased insulin sensitivity were observed in the OGTT with olanzapine but not with OLZ/SAM or placebo. Clamp-derived insulin sensitivity index and weight changes were similar with OLZ/SAM and olanzapine in healthy subjects during the 3-week study. Funding Acknowledgements: This study was funded by Alkermes, Inc.

185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

John M Kane, MD1,2,3; Kimberly E Vanover, PhD4; Suresh Durgam, MD5; Robert Davis, PhD7; Andrew Satlin, MD7; William Rowe, MSN8; Sharon Mates, PhD9; and Carol Tamminga, MD5

1 Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA
2 Division of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA
3 Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
4 Intra-Cellular Therapies, Inc., New York, USA
5 University of Texas Southwestern Medical School, Dallas, Texas, USA

ABSTRACT: Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutamate neurotransmission.